Variation in risk indicators of cardiovascular disease during the menstrual cycle: An investigation of within-subject variations in glutathione peroxidase, haemostatic variables, lipids and lipoproteins in healthy young women

References

• Ciavatti M, Renaud S. Oxidative status and oral contraceptive. Its relevance to platelet abnormalities and cardiovascular risk. Free Radical Biol Med 1991; 10: 325–8
   PubMed Web of Science ®Google Scholar
• Gevers-Leuven JA, Kluft C, Bertina RM, Hessel LW. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 1987; 6: 631–6
   Google Scholar
• Jespersen J, Petsersen KR, Skouby SO. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol 1990; 163: 396–403
   PubMed Web of Science ®Google Scholar
• Seed M. Sex hormones, lipoproteins and cardiovascular risk. Atherosclerosis 1991; 90: 1–7
   Google Scholar
• Karpanou EA, Vyssoulis GP, Georgoudi DG, Toutouza MG, Toutouza PK. Disparate serum lipids changes between normotewive and hypertensive women during the menstrual cycle. Am J Cardiol 1992; 70: 111–13
   Google Scholar
• De Leon RG, Austin KL, Richards L, Guerrero F. Lipid and hormonal profile of Panamanian women during the menstrual cycle. Int J Gynaecol Obstet 1992; 39: 219–26
   Google Scholar
• Kim H-J, Kalkhoff RK. Changes in lipoprotein composition during the menstrual cycle. Metabolism 1979; 28: 663–8
   PubMed Web of Science ®Google Scholar
• Basdevant A, de Ligniers B, Bigorie B, Guy-Grand B. Estradiol, progesterone and plasma lipids during the menstrual cycle. Diabetes et Metabolisme 1981; 7: 1–4
   Google Scholar
• Larsson H, Persson S, Hedner P, Odeberg H, Gustafson A. Studies on blood viscosity during the menstrual cycle and in the postmenopausal period in healthy women. Acta Obstet Gynml Scand 1989; 68: 483–6
   Google Scholar
• Lebech AM, Kjâr A. Lipid metabolism and coagulation during the normal menstrual cycle. Horm Metab Res 1989; 21: 445–8
   Google Scholar
• Lebech AM, Kjær A, Lebech PE. Metabolic changes during the normal menstrual cycle: a longitudinal study. Am J Obstet Gynecol 1990; 163: 414–16
   PubMedGoogle Scholar
• Ygge J. Variation in the individual subject of some parameters in blood coagulation and fibrinolysis. Stand J Haematol 1969; 6: 343–7
   Google Scholar
• Cederblad G, Hahn L, Korsan-Bengtsen K, Pehrsson NG, Rybo G. Variations in blood coagulation, fibrinolysis, platelet function and various plasma proteins during the menstrual cycle. Haemostasis 1977; 6: 294–302
   PubMedGoogle Scholar
• Jespersen J, Ingekg S, Bach E. Antithrombin III and platelets during the normal menstrual cycle and in women receiving oral contraceptives low in oestrogen. Gynecol Obstet Invest 1983; 15: 153–62
   Google Scholar
• Jespersen J, Kluft C. Inhibition of tissue-type plas-minogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle. Thromb Haemost 1986; 55: 388–9
   PubMed Web of Science ®Google Scholar
• Siegbahn A, Odlind V, Hedner U, Venge P. Coagulation and fibrinolysis during the normal menstrual cycle. Uppsala J Med Sci 1989; 94: 137–52
   PubMed Web of Science ®Google Scholar
• Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158–69
   PubMed Web of Science ®Google Scholar
• Beutler E. Red cell metabolism. A manual of biochemical methods.3rd ed. 1984
   Google Scholar
• Landgren BM, Unden AL, Diczfalusy E. Hormonal profile of the cycle in 68 normally menstruating women. Acta EndoCrinol 1980; 94: 89–98
   PubMedGoogle Scholar
• Capel ID, Jenner M, Williams DC, Donaldson D, Nath A. The effect of prolonged oral contraceptive steriode use on erythrocyte glutathione peroxidase activity. J Steroid Biochem 1981; 14: 729–32
   PubMedGoogle Scholar
• Michäelsson G, Edqvist L. Erythrocyte glutathione peroxidase activity in acne vulgaris and the effect of selenium and vitamin E treatment. Acta Dermatol Venereol Stockh 1984; 64: 9–14
   PubMed Web of Science ®Google Scholar
• Refn H, Kjær A, Lebech A, Borggaard B, Schierup L, Bremmelgaard A. Metabolic changes during treatment with two different progestogens. Am J Obstet Gynecol 1990; 163: 374–7
   Google Scholar
• Lobo RA. Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 1990; 75(4)18S–25S
   PubMedGoogle Scholar
• Jern C, Manhem K, Eriksson E, Tengborn L, Risberg B, Jern S. Haemostatic responses to mental stress during the menstrual cycle. Thromb Haemost 1991; 66: 614–18
   PubMed Web of Science ®Google Scholar
• Kim I, Yetley EA, Calvo MS. Variations in iron-status measures during the menstrual cycle. Am J Clin Nutr 1993; 58: 705–9
   PubMed Web of Science ®Google Scholar
• Cullinane EM, Yurgalevitch SM, Saritelli AL, Herbert PN, Thompson PD. Variations in plasma volume affect total and low-density lipoprotein cholesterol during the menstrual cycle. Metabolism 1995; 44: 965–71
   Google Scholar
• Pliner P, Fleming AS. Food intake, body weight and sweetness preference over the menstrual cycle. Physiol Behav 1983; 3: 663–6
   Google Scholar
• Tangney C, Brownie C, Wu S. Impact of menstrual periodicity on serum lipid levels and estimates of dietary intake. J Am Coll Nutr 1991; 10: 107–13
   PubMed Web of Science ®Google Scholar
• Marckmann P, Sandström B, Jespersen J. Effects of total fat content and fatty acid composition in the diet on factor VII coagulant activity and blood lipids. Atherosclerosis 1990; 80: 227–33
   PubMed Web of Science ®Google Scholar
• Miller GJ, Martin JC, Mitropoulos KA, Reeves BEA, Thompson RL, Meade TW, et al. Plasma factor VII is activated by postprandial triglycerida-emia, irrespective of dietary composition. Atherosclerosis 1991; 86: 163–71
   Google Scholar